A tyrosinase activity inhibitor is prepared by combining (A) a metal (zinc, cobalt or iron) chelate compound of α-lipoyl amino acid or its pharmaceutically acceptable salt with (B-1) a human manganese SOD or (B-2) an ascorbic acid compound such as ascorbic acid and ascorbyl glucoside. A ratio (R1) of the (B-1) component content to the (A) component content is preferably 0.001 to 1,500, when R1 is defined as R1=[Unit concentration of (B-1) component (unit/mL)/Concentration of (A) component (μg/mL)], and a ratio (R2) of the (A) component content to the (B-2) component content is preferably 0.0001 to 1,000, when R2 is defined as R2=[Concentration of (A) component (m/mL)/Concentration of (B-1) component (mg/mL)]. An external preparation for skin contains the (A) component and the (B-1) component or the (B-2) component as effective ingredients for inhibiting tyrosinase activity.
将(A)α-脂酰
氨基酸的
金属(
锌、
钴或
铁)螯合物或其药学上可接受的盐与(B-1)人
锰SOD或(B-2)
抗坏血酸化合物如
抗坏血酸和
抗坏血酸葡萄糖苷结合,制备
酪氨酸酶活性
抑制剂。(B-1)组分含量与(A)组分含量之比(R1)优选为 0.001 至 1,500,当 R1 定义为 R1=[(B-1)组分的单位浓度(单位/毫升)/(A)组分的浓度(微克/毫升)],(A)组分含量与(B-2)组分含量之比(R2)优选为 0.0001至1,000,当R2定义为R2=[(A)组分的浓度(m/mL)/(B-1)组分的浓度(mg/mL)]时。一种皮肤外用制剂含有(A)成分和(B-1)成分或(B-2)成分,作为抑制
酪氨酸酶活性的有效成分。